In:
Journal of Virology, American Society for Microbiology, Vol. 82, No. 1 ( 2008-01), p. 86-95
Kurzfassung:
Lentivectors stimulate potent immune responses to antigen transgenes and are being developed as novel genetic vaccines. To improve safety while retaining efficacy, we constructed a lentivector in which transgene expression was restricted to antigen-presenting cells using the mouse dectin-2 gene promoter. This lentivector expressed a green fluorescent protein (GFP) transgene in mouse bone marrow-derived dendritic cell cultures and in human skin-derived Langerhans and dermal dendritic cells. In mice GFP expression was detected in splenic dectin-2 + cells after intravenous injection and in CD11c + dendritic cells in the draining lymph node after subcutaneous injection. A dectin-2 lentivector encoding the human melanoma antigen NY-ESO-1 primed an NY-ESO-1-specific CD8 + T-cell response in HLA-A2 transgenic mice and stimulated a CD4 + T-cell response to a newly identified NY-ESO-1 epitope presented by H2 I-A b . As immunization with the optimal dose of the dectin-2 lentivector was similar to that stimulated by a lentivector containing a strong constitutive viral promoter, targeting antigen expression to dendritic cells can provide a safe and effective vaccine.
Materialart:
Online-Ressource
ISSN:
0022-538X
,
1098-5514
DOI:
10.1128/JVI.01289-07
Sprache:
Englisch
Verlag:
American Society for Microbiology
Publikationsdatum:
2008
ZDB Id:
1495529-5
